T Martini1, P Ströbel, A Steidler, N Petrakopoulou, P Erben, C Bolenz. 1. Klinik für Urologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
Abstract
BACKGROUND: Lymphovascular invasion (LVI) represents a surrogate marker for micrometastatic urothelial carcinoma of the bladder (UCB). OBJECTIVES: We evaluated whether D2-40 immunhistochemistry (IHC) alters detection of LVI when compared to conventional HE (hematoxylin-eosin) staining of UCB specimens in a blinded fashion. MATERIAL AND METHODS: HE- and D2-40-IHC-stained representative sections of 80 patients after radical cystectomy (RC) were re-reviewed. LVI detection rates were recorded and compared after blinded evaluation. RESULTS: LVI was present in 53 patients (66.3%) in HE-stained sections and in 44 patients (55%) in D2-40 stainings. In 13 patients, LVI (16.3%) was found in HE stained sections but not confirmed when IHC was applied (false positive when using IHC as a reference standard). D2-40 IHC identified LVI in 4 additional patients (5%) who were classified as LVI negative in conventional HE staining (false negative). 52 patients (65%) were lymph node negative (pN0), 21 of whom (40.4%) were LVI positive in conventional HE sections and 16 of whom (30.8%) were LVI positive in IHC. In 9 pN0 patients (17.3%), LVI was diagnosed in HE sections but not confirmed by IHC (false positive). D2-40 IHC identified LVI in 4 additional patients (7.7%) who were node negative and classified as LVI negative in conventional HE staining (false negative). In patients who experienced recurrence (n=35) and who were classified as pN0 at the time of RC, HE staining resulted both in false-positive (n=2; 5.7%) and false-negative (n=3; 8.6%) findings. CONCLUSION: Different detection rates of LVI were observed when using IHC with D2-40 in UCB patients compared to conventional HE staining. The routine use of D2-40 IHC should be considered in clinical trial design to improve risk stratification of pN0 patients after RC.
BACKGROUND: Lymphovascular invasion (LVI) represents a surrogate marker for micrometastatic urothelial carcinoma of the bladder (UCB). OBJECTIVES: We evaluated whether D2-40 immunhistochemistry (IHC) alters detection of LVI when compared to conventional HE (hematoxylin-eosin) staining of UCB specimens in a blinded fashion. MATERIAL AND METHODS:HE- and D2-40-IHC-stained representative sections of 80 patients after radical cystectomy (RC) were re-reviewed. LVI detection rates were recorded and compared after blinded evaluation. RESULTS:LVI was present in 53 patients (66.3%) in HE-stained sections and in 44 patients (55%) in D2-40 stainings. In 13 patients, LVI (16.3%) was found in HE stained sections but not confirmed when IHC was applied (false positive when using IHC as a reference standard). D2-40 IHC identified LVI in 4 additional patients (5%) who were classified as LVI negative in conventional HE staining (false negative). 52 patients (65%) were lymph node negative (pN0), 21 of whom (40.4%) were LVI positive in conventional HE sections and 16 of whom (30.8%) were LVI positive in IHC. In 9 pN0 patients (17.3%), LVI was diagnosed in HE sections but not confirmed by IHC (false positive). D2-40 IHC identified LVI in 4 additional patients (7.7%) who were node negative and classified as LVI negative in conventional HE staining (false negative). In patients who experienced recurrence (n=35) and who were classified as pN0 at the time of RC, HE staining resulted both in false-positive (n=2; 5.7%) and false-negative (n=3; 8.6%) findings. CONCLUSION: Different detection rates of LVI were observed when using IHC with D2-40 in UCB patients compared to conventional HE staining. The routine use of D2-40 IHC should be considered in clinical trial design to improve risk stratification of pN0 patients after RC.
Authors: Matthias May; Maximilian Burger; Sabine Brookman-May; Christian G Stief; Hans-Martin Fritsche; Jan Roigas; Mario Zacharias; Markus Bader; Philipp Mandel; Christian Gilfrich; Michael Seitz; Derya Tilki Journal: Clin Genitourin Cancer Date: 2013-11-13 Impact factor: 2.872
Authors: Christian Bolenz; Mario I Fernández; Derya Tilki; Edwin Herrmann; Julia Heinzelbecker; Süleyman Ergün; Philipp Ströbel; Oliver Reich; Maurice S Michel; Lutz Trojan Journal: BJU Int Date: 2009-07-08 Impact factor: 5.588
Authors: Mario I Fernández; Christian Bolenz; Lutz Trojan; Annette Steidler; Christel Weiss; Peter Alken; Rainer Grobholz; Maurice Stephan Michel Journal: Eur Urol Date: 2007-08-24 Impact factor: 20.096
Authors: G G Van den Eynden; I Van der Auwera; S J Van Laere; C G Colpaert; P van Dam; L Y Dirix; P B Vermeulen; E A Van Marck Journal: Br J Cancer Date: 2006-06-05 Impact factor: 7.640